Presentation at Jefferies London Healthcare Conf

hVIVO PLC

05 November 2024

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

hVIVO to present at Jefferies London Healthcare Conference

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Yamin 'Mo' Khan, Chief Executive Officer, will be presenting in-person at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT. Alongside the presentation, the Company will also be available for one-to-one meetings.

The Jefferies Conference is the largest healthcare-dedicated conference in Europe. The conference hosts over 650 healthcare companies, 3,000 attendees, and nearly 8,000 investor and business-to-business meetings. The conference will feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.

For further information please contact:

hVIVO plc		[phone]
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				[phone]
Geoff Nash, Camilla Hume, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)			[phone]
James Steel, Dr Christopher Golden
Davy (Euronext Growth Adviser and Joint Broker)			[phone]
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) Paul McManus / Phillip Marriage / Louis Ashe-Jepson		[phone] or [e-mail] [phone] / [phone] / [phone]

Notes to Editors

hVIVO plc (ticker: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

 

END